Showing results (51-60 of 196) with videos related to

Sort By:
Pageof 20
The American Journal of Surgical Pathology|July 19, 2017
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK FusionsJaclyn F Hechtman, Ryma Benayed, David M Hyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2012
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutationsNatasha Rekhtman, Paul K Paik, Maria E Arcila, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancersAnya M Litvak, Paul K Paik, Kaitlin M Woo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 16, 2015
Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2)Jaclyn F Hechtman, Weiguo Liu, Justyna Sadowska, et al.
The Journal of Pathology|January 31, 2018
The value of cell-free DNA for molecular pathologyCaitlin M Stewart, Prachi D Kothari, Florent Mouliere, et al.
Molecular Cancer Therapeutics|December 3, 2011
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profilingJamie E Chaft, Maria E Arcila, Paul K Paik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2015
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing ApproachesAlexander Drilon, Lu Wang, Maria E Arcila, et al.
Molecular Cancer Research : MCR|December 15, 2015
Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAFJaclyn F Hechtman, Ahmet Zehir, Rona Yaeger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2011
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinibGeoffrey R Oxnard, Yelena Y Janjigian, Maria E Arcila, et al.
Acta Oncologica (Stockholm, Sweden)|July 27, 2019
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancersSebastian Mondaca, Michael Offin, Laetitia Borsu, et al.
Pageof 20